Merck

Merck launches Vivera in Latin America

MerckMerck, a leading science and technology company, today announced the launch of its new consumer brand Vivera® in Latin America. Vivera is being launched first in Chile in January 2016, to be followed by several major Latin American markets later in 2016. Vivera provides fast relief from a gastro-intestinal upset by accelerating the natural healing process.

Merck formulated Vivera with B.Aliv®, one of the most researched and most effective probiotics in the world for the treatment of gastro-intestinal upset, which works by regenerating the intestinal flora. The Vivera food supplement comes in a practical and innovative ready-to-use powder sachet, making it an ideal choice for children and adults to use anywhere on-the-go.

Uta Kemmerich-Keil, President and CEO of the Consumer Health business of Merck, commented: "We truly look forward to launching Vivera! Vivera is a fantastic probiotic product which accelerates the healing process after a gastro-intestinal upset and restores the function of the digestive system naturally. I am confident that we have a truly winning proposition for both children and adults, particularly when looking for natural and effective options."

Brand transitions from Biopharma to Consumer Health
Also in Latin America, Merck announced a second wave of brand transfers from its Biopharma business to the Consumer Health business. These start from January 2016 onwards in Colombia, Ecuador and Peru and then in 2017 in Chile. The brands involved in the transfer are Anemidox® / Confer®, a treatment and prevention of iron deficiency related anemia at every stage of life; and Hepabionta®, a liver protector.

Uta Kemmerich-Keil explained, "We have decided to transfer these brands as all of them have great potential for consumerization. Leveraging this approach, we will further develop these brands and thereby generate further growth."

About Merck's Consumer Health Business
Brands of the Consumer Health business, such as Dolo-Neurobion®, Neurobion®, Bion®, Seven Seas®, Nasivin®, and Femibion® are innovative leaders in key markets, backed by science and trusted by consumers worldwide. The Consumer Health business is with over 2,700 employees globally active in over 40 markets. Since 2014, the portfolio comprises of brands with annual total sales of about $ 1 billion. Consumer Health is a business of the Healthcare business sector within the Merck Group with global headquarters in Darmstadt, Germany.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Boehringer Ingelheim increases acce…

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an eas...

Read more

FDA approves first buprenorphine im…

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designe...

Read more

Fasting-like diet reduces multiple …

Evidence is mounting that a diet mimicking the effects of fasting has health benefits beyond weight loss, with a new USC-led study indicating that it may reduce symptoms ...

Read more

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Exercise, future anticancer therapy…

Several studies have demonstrated the benefits of exercise to improve the quality of life of people with cancer. But Dr. Fred Saad, urologist-oncologist and researcher at...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

New class of protein could treat ca…

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therap...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]